Genmab 'Celebrating' Return Of Worldwide HuMax-CD4 Rights July 2, 2007 By Jennifer Boggs Genmab A/S said it is moving full steam ahead with its late-stage HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full rights to the drug from partner Merck Serono SA. (BioWorld Today)Read More
Biotech-Big Pharma Collaborations: Modified And Terminated Agreements, May 25 - June 28, 2007# July 2, 2007
Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: May 25 - June 28, 2007# July 2, 2007
RSS